Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Benchtop Cell Sorter Validated in Biosafety Containment Setting

By LabMedica International staff writers
Posted on 27 Dec 2021
Fluorescent-activated cell sorting (FACS) is often the most appropriate technique to obtain pure populations of a cell type of interest for downstream analysis. More...
The ability to sort pure populations of immune cells is a critical tool for immunologists.

Aerosol droplets can be generated during the sort, which poses a biosafety risk when working with samples containing risk group 3 pathogens such as Francisella tularensis, Mycobacterium tuberculosis, Yersinia pestis, and severe acute respiratory syndrome coronavirus 2.

Pulmonary pathogen specialists at the Rocky Mountain Laboratories (Hamilton, MT, USA) performed aerosol testing as part of the biosafety evaluation of the MACSQuant Tyto (Miltenyi Biotec, Bergisch Gladbach, Germany) a completely closed, cartridge-based cell sorter. They also established quality control procedures to routinely evaluate instrument performance. Aerosol testing was performed on FACSAria II (BD Biosciences, San Diego, CA, USA) with the Aerosol Management System disabled as a positive control for aerosol generation.

The scientists reported that before usage of the Tyto on the benchtop to sort cells at BSL-3, it was necessary to empirically determine if aerosols were generated during the cell sort procedure. They utilized a novel method using internally fluorescent 1.0 μm beads to perform aerosol testing on the Tyto. These beads were uniform in size and intensely fluorescent in the fluorescein isothiocyanate (FITC) channel.

As a positive control, they detected aerosols generated by the in-house FACSAria II when the Aerosol Management System was disabled, and the flow stream disrupted. As expected, beads were detected on the coverslip after only a 30-second exposure. The MACSQuant Tyto did not produce aerosols as part of the sort procedure. The scientists established a purity of >96%, depletion yield of >80%, and sort efficiency of >85% as benchmarks that must be met during quality control testing.

The authors concluded that they utilized the Tyto cell sorter in their BSL-3 laboratory. This instrument not only has a small footprint but most importantly does not generate aerosols during the sort procedure. The use of this technology will improve current immunological studies in containment laboratories by allowing a greater number of scientific groups to isolate cell types involved in the immune response to high-consequence pathogens for downstream applications. The study was published on November 24, 2021 in the journal Applied Biosafety.

Related Links:
Rocky Mountain Laboratories
Miltenyi Biotec
BD Biosciences



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.